tbuckley/cabot-search huggingface dataset:
NCCN Debuts New Guidelines for Myeloproliferative Neoplasms
Authors: Ruben A. Mesa
Journal: Journal of the National Comprehensive Cancer Network (2017)

For the first time, NCCN has published guidelines specifically geared toward treating myeloproliferative neoplasms (MPNs). The first set of guidelines was developed for myelofibrosis (MF), and was presented at the NCCN 22nd Annual Conference. Future guidelines will be issued for polycythemia vera, essential thrombocytopenia, and atypical MPNs. Patients with MF can have an unpredictable course, one that is largely dependent on the presence of certain molecular alterations. Models are currently emerging that take into account molecular factors. Only one drug is currently approved for MF, the oral JAK1/2 inhibitor ruxolitinib, which has been shown to significantly reduce splenomegaly and improve symptoms.
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
Authors: Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Masahiko Tanaka, Makoto Akimoto, Kazue Nakamura, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino, Koji Abe, Masashi Aoki, Shoji Tsuji, Yasuto Itoyama, Gen Sobue, Masanori Togo, Chikuma Hamada, Hidenao Sasaki, Ichiro Yabe, Shizuki Doi, Hitoshi Warita, Takashi Imai, Hiroaki Ito, Mitsumasa Fukuchi, Etsuko Osumi, Manabu Wada, Imaharu Nakano, Mitsuya Morita, Katsuhisa Ogata, Yuichi Maruki, Kimiko Ito, Osamu Kano, Mineo Yamazaki, Yuji Takahashi, Hiroyuki Ishiura, Mieko Ogino, Ryoko Koike, Chiho Ishida, Tsuyoshi Uchiyama, Kouichi Mizoguchi, Tomokazu Obi, Hirohisa Watanabe, Naoki Atsuta, Ikuko Aiba, Akira Taniguchi, Hideyuki Sawada, Takanori Hazama, Harutoshi Fujimura, Hirofumi Kusaka, Takenobu Kunieda, Hitoshi Kikuchi, Hidenori Matsuo, Hidetsugu Ueyama, Kazutoshi Uekawa, Masahiko Tanaka, Makoto Akimoto, Masaki Ueda, Aiko Murakami, Rie Sumii, Takuya Kudou, Kazue Nakamura, Kazunori Morimoto, Takatomo Yoneoka, Manabu Hirai, Kouichi Sasaki, Hidetomo Terai, Tomoko Natori, Hiroshi Matsui, Kuniko Kotani, Kaori Yoshida, Tomohisa Iwasaki, Fumihiro Takahashi, Kazuoki Kondo, Hiide Yoshino
Journal: The Lancet Neurology (2017)
Intubation During In-Hospital Cardiac Arrest
Authors: Jeffrey L. Wilt, Deborah Lee
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massive Polio Vaccination Drive in African Nations
Authors: M.J. Friedrich
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Meta View on Meta-analyses
Authors: W. Wolfgang Fleischhacker
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
Authors: Jihyun An, Kwang Sun Lee, Kang Mo Kim, Do Hyun Park, Sang Soo Lee, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee
Journal: Clinical and Molecular Hepatology (2017)

Background/Aims Little is known about the treatment or outcomes of hepatocellular carcinoma (HCC) complicated with bile duct invasion. Methods A total of 247 consecutive HCC patients with bile duct invasion at initial diagnosis were retrospectively included. Results The majority of patients had Barcelona Clinic Liver Cancer (BCLC) stage C HCC (66.8%). Portal vein tumor thrombosis was present in 166 (67.2%) patients. Median survival was 4.1 months. Various modalities of treatment were initially employed including surgical resection (10.9%), repeated transarterial chemoembolization (TACE) (42.5%), and conservative management (42.9%). Among the patients with obstructive jaundice (n=88), successful biliary drainage was associated with better overall survival rate. Among the patients with BCLC stage C, overall survival differed depending on the initial treatment for HCC; surgical resection, TACE, systemic chemotherapy, and conservative management showed overall survival rates of 11.5, 6.0 ,2.4, and 1.6 months, respectively. After adjusting for confounders, surgical resection and repeated TACE were significant prognostic factors for HCC patients with bile duct invasion (hazard ratios 0.47 and 0.39, Ps <0.001, respectively). Conclusions The survival of HCC patients with bile duct invasion at initial diagnosis is generally poor. However, aggressive treatments for HCC such as resection or biliary drainage may be beneficial therapeutic options for patients with preserved liver function. Keywords: Hepatocellular carcinoma; Bile duct invasion; Treatment; Prognosis; Obstructive jaundice
ReGel® polymer-based delivery of interleukin-2 as a cancer treatment.
Authors: Wolfram E. Samlowski, John R. McGregor, Maria Jurek, Miroslav Baudys, Gaylen M. Zentner, Kirk Fowers
Journal: Cancer Research (2006)

5570  ReGel is an aqueous, filter sterilizable ABA tri-block polymer consisting of poly-(lactide-co-glycolide)(PLG) and polyethylene glycol (PEG). We tested the suitability of this polymer to provide sustained IL-2 delivery for cancer immunotherapy. ReGel/IL-2 is liquid at or below room temperature, and is easily injectable through narrow gauge needles, but undergoes a reversible thermal transition into a bioerodible depot at body temperature. We demonstrated that ReGel/IL-2 releases IL-2 over 72–96h in vitro, without loss of bioactivity. Pharmacokinetic studies following peritumoral injection of 0.1 ml ReGel/IL-2 in mice demonstrated an early burst of IL-2 release, followed by more sustained release kinetics over 96h (T1/2β 48h). Less than 1.5% of the injected dose was detectable in blood or kidneys during the first 48h. A single peritumoral dose of ReGel/IL-2 (1–4 million IU ReGel/IL-2, split into 4 quadrant injections) produced a dose-dependent decrease in tumor growth and improved survival in mice with subcutaneous RD-995 spindle cell carcinoma. Only the highest dose of ReGel/IL-2 tested (4.0 million IU) resulted in significant hypotension. Weekly treatment of Meth A fibrosarcoma and RENCA renal carcinoma with ReGel/IL-2 (2 million IU/dose) induced a significant reduction in tumor growth and improved survival. Reduction in tumor growth at implants remote from injected lesions was also observed, suggesting systemic activation of antitumor immunity. These findings establish that peritumoral injection of ReGel/IL-2 is an effective delivery system for cancer immunotherapy, while decreasing IL-2 toxicity. This polymer delivery system is likely to be broadly applicable for sustained delivery of other cytokines and peptides.
An Irish breast cancer survivorship study: Are we meeting our patients' needs?
Authors: Jarushka Naidoo, Ellen Hayes, MinYuen Teo, Paula Calvert, Anne M. Horgan, Miriam O'Connor
Journal: Journal of Clinical Oncology (2013)

e20687 Background: Breast cancer survivors account for the majority of cancer survivors in Ireland. There are no published data on the issues facing this group of patients. This study investigates the needs of a cohort of Irish breast cancer survivors who completed hospital-based follow-up and were recently discharged to their general practitioners (GP’s.) Physical, psychological, social and spiritual concerns were investigated. Secondary aims were to assess patient satisfaction with discharge from hospital-based services, satisfaction with GP follow-up, and the benefit of a survivorship discharge pack. Methods: A cohort of patients in the South East Cancer Centre was identified. Inclusion criteria were: a history of localized breast cancer, completion of adjuvant therapy within the last 5 years, and discharge to the patient’s GP in the last 6 years. An anonymous questionnaire was developed from standardized survivorship questionnaires, and ethical approval obtained. Subgroup analyses were completed for age and time since diagnosis using Fisher’s exact and Cochran-Armitage tests. Results: 80 patients were identified. 44 patients (55%) completed and returned the questionnaire. 5 patients were excluded (6%). The median age was 53 years (range: 41-65 years.) The commonest concerns were fatigue (51%), fear of recurrence (69%) and concerns regarding second cancers (69%.) 23 patients (59%) were satisfied with discharge to their GP and 25 patients (64%) were content with GP follow-up. 23 patients (59%) reported that a treatment summary would be of benefit. 27 patients (67%) felt they would benefit from a discharge pack. Patients under 60 years of age were more likely to report physical concerns (p=0.012). Patients reported fewer physical and psychological concerns over time after diagnosis (p-trend &lt;0.001). Conclusions: This is the first Irish breast cancer survivorship study. Irish breast cancer survivors had ongoing concerns, but were satisfied with GP follow-up care. The current model of care could potentially be improved by the provision of a discharge pack that includes a treatment summary.
Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Analysis of a prospective ANOCEF randomized phase II trial.
Authors: Emeline Tabouret, Caroline Houillier, Nadine Martin-Duverneuil, Marie Blonski, Carole Soussain, Herve Ghesquieres, Roch Houot, Vincent Delwail, Pierre Soubeyran, Remy Gressin, Emmanuel Gyan, Olivier L. Chinot, Luc Taillandier, Marie-Laure Tanguy, Antonio Marcilio Padula Omuro, Khê Hoang-Xuan
Journal: Journal of Clinical Oncology (2015)

2035 Background: Detailed neuro-imaging analyses of PCNSL are limited. Our objective was to evaluate MRI findings in PCNSL patients treated with hdMTX without radiotherapy, with a particular emphasis on T2-FLAIR MRI abnormalities. Methods: We reviewed MRI (T1, T1 post-gadolinium and T2/FLAIR) findings of 85 patients with PCNSL enrolled in a randomized multicenter phase II trial (NCT00503594) evaluating two hdMTX regimens (MPV-A and MTX-temozolomide), conducted in patients aged 60 and older. Response rate (IPCG criteria), number and volume of enhancing lesions, anatomical site, site of relapse and patterns of relapse were analyzed and correlated with outcome. Landmark analyses were performed at 2 and 4 months. Results: Objective responses (OR) were: complete response (CR): 56%, uncertain CR: 4%, partial response: 18%, stable disease: 7%, progressive disease: 15%. On multivariate analysis, location in the posterior fossa (p = 0.008) and tumor volume (p = 0.006), but not lesion number, were significantly associated with survival. OR at the first MRI (2months) and at the end of treatment (4 months) were significantly associated with overall survival in multivariate analysis (p < 0.001 and p = 0.004 respectively). Early versus delayed CR did not impact survival. Relapse in the brain involved the initial enhancing site, a site at distance, or both in 46%, 40% and 14% respectively. At baseline, non-enhancing T2-FLAIR hypersignal lesions at distance from the enhancing tumor site were detected in 18 patients (23%), among whom 16 (88%) displayed a marked decrease ( > 50%) after chemotherapy, confirming their neoplastic nature. Among these 18 patients, ten relapsed, and the initially non-enhancing T2-FLAIR lesions corresponded to the site of an enhancing relapse in half of them (N = 5). Conclusions: Relapse after hdMTX at distance from the initial enhancing tumor is frequent and may occur in the area of non-enhancing T2-FLAIR hyper-intensity identified at distance from the enhancing tumor at baseline. Future response criteria should take into consideration non-enhancing T2-Flair lesions.
Apnea and Respiratory Distress in the Newborn Infant
Authors: C. D. Cook, J. F. Lucey, J. E. Drorbaugh, S. Segal, J. M. Sutherland, C. A. Smith
Journal: New England Journal of Medicine (1956)

Specific Technics of Resuscitation and Artificial RespirationAs indicated in the preceding discussion, technics for aiding respiration should be considered according to whether they are methods for initiating breathing, methods for supplementing the infant's own efforts during respiratory distress or methods for preventing the development of such respiratory distress. Obviously, there is considerable overlap between these three general approaches to therapy. The following two sections deal in detail with the individual methods, their theoretical applicability, their practicality and, where available, critical data on actual use. It will be apparent that there are multiple difficulties in such an evaluation and that . . .
The Effect of Monochromatic Infrared Energy on Sensation in Subjects With Diabetic Peripheral Neuropathy: A Double-Blind, Placebo-Controlled Study
Authors: Judy K. Clifft, Richard J. Kasser, Timothy S. Newton, Andrew J. Bush
Journal: Diabetes Care (2006)

We thank Dr. Burke (1) for his thoughtful comments and critical review of our research study (2). In responding to his comments, we have addressed each of his stated concerns in order.

First, regarding the level of photo energy delivered, the manufacturer preset our active monochromatic infrared energy (MIRE) units to deliver the recommended 6–8 bars of energy or 1.95 J · cm−2 · min−1 for 30 min (total energy of 58.5 J/cm2), whereas the MIRE units used in the Leonard study (2) delivered 1.3 J · cm−2 · …
Yvonne Gladys Mukasa
Authors: Stephanie Ogden, Robert Chalmers
Journal: BMJ (2017)

Yvonne Gladys Mukasa was a talented pupil. An alumna of Howell’s School in Cardiff, she excelled in a variety of activities, including playing the violin, and she was a member of the youth orchestra in south Wales. She went on to obtain a scholarship to undertake A levels at Malvern College.

After qualifying from Manchester University in 2001 she developed an interest in dermatology while working as a senior house officer at Salford Royal Hospital. She undertook …
Metastases From Colorectal Cancer Avid on 68Ga-PSMA PET/CT
Authors: Lise Hangaard, Mads Ryø Jochumsen, Mikkel Holm Vendelbo, Kirsten Bouchelouche
Journal: Clinical Nuclear Medicine (2017)

68Ga-PSMA PET/CT is currently used for detection of prostate cancer including metastases, even at low prostate-specific antigen values. A grown number of reports have shown increased uptake of PSMA in neovessels of nonprostatic malignancies including lung cancer, and recently a case report has demonstrated increased PSMA uptake in colorectal adenocarcinoma. In this case report, we demonstrate increased 68Ga-PMSA uptake on PET/CT in metastases from previously treated colon adenocarcinoma, and it illustrates the importance of histology of suspicious lesions on 68Ga-PSMA PET/CT.
Head and Neck Cancers, Version 1.2015
Authors: David G. Pfister, Sharon Spencer, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Robert L. Foote, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks, Ying J. Hitchcock, Antonio Jimeno, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Thomas McCaffrey, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Cristina P. Rodriguez, Sandeep Samant, Jatin P. Shah, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole McMillian, Miranda Hughes
Journal: Journal of the National Comprehensive Cancer Network (2015)

These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Head and Neck (H&N) Cancers. These Insights describe the different types of particle therapy that may be used to treat H&N cancers, in contrast to traditional radiation therapy (RT) with photons (x-ray). Research is ongoing regarding the different types of particle therapy, including protons and carbon ions, with the goals of reducing the long-term side effects from RT and improving the therapeutic index. For the 2015 update, the NCCN H&N Cancers Panel agreed to delete recommendations for neutron therapy for salivary gland cancers, because of its limited availability, which has decreased over the past 2 decades; the small number of patients in the United States who currently receive this treatment; and concerns that the toxicity of neutron therapy may offset potential disease control advantages.
Intracellular delivery of oligonucleotides in Helicobacter pylori by fusogenic liposomes in the presence of gastric mucus
Authors: Rita S. Santos, George R. Dakwar, Elisa Zagato, Toon Brans, Céu Figueiredo, Koen Raemdonck, Nuno F. Azevedo, Stefaan C. De Smedt, Kevin Braeckmans
Journal: Biomaterials (2017)
PTU-087 Poster presentations: an effective way of disseminating research?: Abstract PTU-087
Authors: J R Goodhand, M Wahed, C Giles, L Langmead, P M Irving, D S Rampton
Journal: Gut (2010)

<h3>Introduction</h3> Posters are used at conferences to convey an overview of clinical and scientific research. Previously we have shown that only a minority of delegates visit an individual poster, and often only for social reasons.1 We aimed to assess the memorability of poster presentations and to identify aesthetic factors that increase their visual appeal. <h3>Methods</h3> 6 abstracts were randomly selected from the inflammatory bowel diseases (IBD) clinical section of the 2009 Digestive Diseases Week (DDW) meeting. 25 British delegates with an interest in IBD scored each poster for its scientific merit, originality and aesthetic qualities on 5 cm visual analogue scales. Two weeks later recall of the study populations, experimental designs and conclusions was assessed by cold-calling, using six point Liekert scales (maximum score 18). <h3>Results</h3> Overall, recall of poster contents was poor, although comparable for a poster of distinction (mean 3.5 (SEM 0.8)) and the delegates9 highest (3.9 (0.9)) and lowest (3.1 (0.6)) ranked posters. Positive correlations between aesthetic scores and both scientific merit (r=0.25, p=0.02) and originality (r=0.31, p&lt;0.0001) were seen. Univariate analysis using stepwise forward regression was used to identify visually appealing poster characteristics (Abstract 087). Multivariate analysis confirmed that the aesthetic score was influenced by the perceived scientific content; every unit increase in scientific content resulted in a 0.15 (95% CI 0.05 to 0.25, p=0.002) parameter estimate (PE) increase in aesthetic score. Similarly, the presence of one or more pictures/graphs improved the aesthetic score by 1.3 (95% CI 0.49 to 2.12, p=0.002). In contrast, as the number of words increased, the aesthetic score reduced (PE −16.4, 95% CI −25.8 to −6.7, p=0.001). <h3>Conclusion</h3> Expert delegates when asked to scrutinise posters in detail recall little of their contents. Researchers need to produce posters that are visually appealing; aesthetic appeal improves with the inclusion of pictures but not tables, and a lack of overcrowding. What is not clear is whether the scientific content improves the aesthetics or whether a well presented poster improves the perceived scientific content.
Classification and Causes of Perinatal Mortality: Part II. Factors in Pregnancy and Labour Influencing Perinatal Mortality. Part III. Clinical Pictures in Babies Dying in the Neonatal Period
Authors: J. P. Bound, N. R. Butler, W. G. Spector
Journal: BMJ (1956)

Here some of the factors shown in Table V to be of importance in perinatal mortality are discussed from the clinical aspect.the possibility of fatal birth trauma.The way in which high maternal age operates remains obscure.Toxaemia is a known association of pregnancy in mothers over 35 years (Eastman, 1950) and analysis of our figures suggested that while this association could account for some of the deaths in the group of ante-partum death with maceration only it could not account for the increased loss of babies from ante-partum asphyxia and birth trauma with high maternal age.However, the figures relating to this analysis were not statistically significant.Over the age of 35 birth trauma was not related to any particular complication of labour.Most of the common difficulties were encountered.In particular, birth trauma after an apparently normal labour bore no relationship to maternal age.